术前肉毒毒素A与渐进性气腹在巨大腹壁疝筋膜关闭中的系统评价与荟萃分析
该系统评价与荟萃分析纳入20项研究,评估术前渐进性气腹或肉毒毒素A注射在腹壁疝修补中的围手术期疗效。总体筋膜关闭率为0.94(95%CI 0.89-0.98),累积复发率为0.03(95%CI 0.01-0.06)。肉毒毒素A适合低门槛使用,而渐进性气腹因并发症较多应谨慎使用,但纳入研究质量低且缺乏对比信息,无法做出确定性推荐。
要点
- 术前肉毒毒素A或渐进性气腹可促进巨大腹壁疝筋膜关闭,总体关闭率0.94。
- 肉毒毒素A并发症少适合低门槛使用,渐进性气腹并发症多且有时严重应谨慎。
- 纳入研究质量低、存在偏倚且缺乏对比信息,无法做出确定性推荐。
核心结论
- 术前渐进性气腹和肉毒毒素A可促进筋膜关闭且不引起大量不良事件。
- 肉毒毒素A适合低门槛使用,渐进性气腹因并发症较多应谨慎使用。
- 因纳入研究质量低、存在偏倚且对比信息稀缺,无法做出确定性推荐。
研究设计与样本
- 系统评价与荟萃分析,系统检索Embase、Medline Ovid、Web of Science、Cochrane Central和Google Scholar。
- 从905项识别研究中纳入20项研究,包括渐进性气腹(n=11)、肉毒毒素A(n=6)及两者联合(n=3)。
- 纳入标准为英文报告成人腹壁疝修补术前使用渐进性气腹或肉毒毒素A的筋膜关闭、适应证、并发症或术后结局研究。
- 使用牛津证据水平指南和MINORS标准评估研究质量,采用随机效应模型计算合并筋膜关闭率和复发率。
- 已在PROSPERO注册,注册号CRD42020181679。
主要发现
- 总体筋膜关闭率为0.94(95%CI 0.89-0.98)。
- 累积报告复发率为0.03(95%CI 0.01-0.06)。
- 渐进性气腹的报告并发症较多且有时严重,而肉毒毒素A则相反。
- 使用渐进性气腹或肉毒毒素A的适应证基于客观(如CT测量)或主观(如预判手术困难)指标。
关键数值与推荐
- 总体筋膜关闭率0.94(95%CI 0.89-0.98)。
- 累积复发率0.03(95%CI 0.01-0.06)。
- 肉毒毒素A适合低门槛使用。
- 渐进性气腹应谨慎使用,因并发症较多且有时严重。
临床怎么用
- 术前肉毒毒素A可考虑低门槛用于巨大腹壁疝以促进筋膜关闭。
- 术前渐进性气腹应谨慎选择患者,因其并发症较多且有时严重。
- 适应证可基于CT测量等客观指标或预判手术困难等主观指标。
局限性
- 纳入研究质量低。
- 存在偏倚。
- 对比信息稀缺。
- 无法做出确定性推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The primary objective was to assess the perioperative efficacy of the preoperative use of progressive pneumoperitoneum or Botulinum Toxin A injections in ventral hernia repair. METHODS: Embase, Medline Ovid, Web of Science, Cochrane Central, and Google Scholar were systematically searched. Studies in English reporting on fascial closure, indications, complications or postoperative outcomes in adult patients that had undergone progressive pneumoperitoneum, Botulinum Toxin A injections, or both before ventral hernia repair were included. Study quality was assessed with the Oxford Levels of Evidence guidelines and the Methodological Index for Non-Randomized Studies criteria. A pooled fascial closure rate and recurrence rate were calculated with random effects models. RESULTS: Twenty studies were included from the 905 identified, comprising the use progressive pneumoperitoneum (n = 11), Botulinum Toxin A (n = 6), and both techniques (n = 3). The overall fascial closure rate was 0.94 (95% confidence interval 0.89-0.98). Indications for the use of progressive pneumoperitoneum or Botulinum Toxin A were based on objective (eg, computed tomography measurements) or subjective measures (eg, foreseen surgical problems). In contrast to the use of Botulinum Toxin A, reported complications with the use of progressive pneumoperitoneum were ample and sometimes severe. The cumulative reported recurrence rate was 0.03 (95% confidence interval 0.01-0.06). CONCLUSION: Preoperative progressive pneumoperitoneum and Botulinum Toxin A can facilitate fascial closure without causing significant numbers of adverse events. Botulinum Toxin A qualifies for low-threshold use, yet progressive pneumoperitoneum should be used cautiously owing to a larger number of complications. Definitive recommendations cannot be made as the quality of included studies is low, bias is present, and comparative information is scarce. Registration number Information about the design and conduct of this systematic review has been registered on PROSPERO, registration number CRD42020181679.
引用
- van Rooijen MMJ, Yurtkap Y, Allaeys M, et al. Fascial closure in giant ventral hernias after preoperative botulinum toxin a and progressive pneumoperitoneum: A systematic review and meta-analysis. Surgery. 2021. PMID: 33888320. doi:10.1016/j.surg.2021.03.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。